In the past two years, I have written several times about Aratana Therapeutics (Nasdaq: PETX ) – a pet therapeutics company that is focused on developing and commercializing innovative therapeutics for cats and dogs. So far, an investment in Aratana Therapeutics was not so lucrative and especially the last six months showed a horrible performance of the stock. In 2016, the stock price was even lower, but in the last few weeks Aratana Therapeutics was trading again close to its all-time lows.